|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 6/01/15 AMERI Holdings, Inc. 8-K:1,2,3,4 5/26/15 15:1.9M Olshan Frome Wolosky LLP |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 365K 2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 58K 3: EX-4.2 Instrument Defining the Rights of Security Holders HTML 57K 4: EX-10.1 Material Contract HTML 50K 5: EX-10.2 Material Contract HTML 65K 6: EX-10.3 Material Contract HTML 44K 7: EX-10.4 Material Contract HTML 20K 8: EX-10.5 Material Contract HTML 20K 9: EX-10.6 Material Contract HTML 35K 10: EX-10.7 Material Contract HTML 25K 11: EX-10.8 Material Contract HTML 122K 12: EX-16.1 Letter re: Change in Certifying Accountant HTML 9K 13: EX-21.1 Subsidiaries of the Registrant HTML 8K 14: EX-99.1 Miscellaneous Exhibit HTML 159K 15: EX-99.2 Miscellaneous Exhibit HTML 97K
|
Unaudited Pro Forma Consolidated Balance Sheet
|
||||||||||||||||||
|
Ameri Holdings, Inc.
|
Ameri &
Partners, Inc.
|
Notes
|
Pro Forma
Adjustments
|
Pro Forma
Combined
|
||||||||||||||
|
ASSETS
|
||||||||||||||||||
|
Current assets:
|
||||||||||||||||||
|
Cash and cash equivalents
|
$ | 3,898 | $ | 825,621 | $ | - | $ | 829,519 | ||||||||||
|
Accounts receivable
|
- | 2,981,574 | - | 2,981,574 | ||||||||||||||
|
Other current assets
|
- | 180,622 | - | 180,622 | ||||||||||||||
|
Total current assets
|
3,898 | 3,987,817 | - | 3,991,715 | ||||||||||||||
|
Investments
|
- | 340,000 | 340,000 | |||||||||||||||
|
Fixed assets
|
- | 29,906 | - | 29,906 | ||||||||||||||
|
Intangible assets-net
|
- | 100,000 | - | 100,000 | ||||||||||||||
|
Security deposit
|
- | 3,750 | - | 3,750 | ||||||||||||||
|
TOTAL ASSETS
|
$ | 3,898 | $ | 4,461,473 | $ | - | $ | 4,465,371 | ||||||||||
|
LIABILITIES AND STOCKHOLDER'S EQUITY
|
||||||||||||||||||
|
Current liabilities:
|
||||||||||||||||||
|
Accounts payable
|
$ | 10,344 | $ | 2,936,608 | $ | 2,946,952 | ||||||||||||
|
Other current liabilities
|
- | 146,791 | - | 146,791 | ||||||||||||||
|
Taxes payable
|
- | 405,218 | - | 405,218 | ||||||||||||||
|
Total current liabilities
|
10,344 | 3,488,617 | - | 3,498,961 | ||||||||||||||
|
Stockholder's equity:
|
||||||||||||||||||
|
Preferred shares
|
- | - | - | |||||||||||||||
|
Common stock
|
154,099 | 992 | a | (30,091 | ) | 125,000 | ||||||||||||
|
Additional paid-in capital
|
47,268,208 | 134,008 | a | (47,398,662 | ) | 3,554 | ||||||||||||
|
Accumulated deficit
|
(47,428,753 | ) | 837,856 | a | 47,428,753 | 837,856 | ||||||||||||
|
Total stockholder's deficit
|
(6,446 | ) | 972,856 | - | 966,410 | |||||||||||||
|
TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT
|
$ | 3,898 | $ | 4,461,473 | $ | - | $ | 4,465,371 | ||||||||||
|
See Notes to Unaudited Pro Forma Consolidated Financial Statements
|
||||||||||||||||||
|
Unaudited Pro Forma Combined Statement of Operations
|
||||||||||||||||
|
For the Year Ended March 31, 2015
|
||||||||||||||||
|
Ameri
Holdings, Inc.
|
Ameri &
Partners, Inc.
|
Pro Forma
Adjustments
|
Pro Forma
Combined
|
|||||||||||||
|
Revenue
|
$ | - | $ | 6,804,379 | $ | - | $ | 6,804,379 | ||||||||
|
Cost of revenue
|
- | 15,114,400 | - | 15,114,400 | ||||||||||||
|
Gross profit
|
- | 1,689,979 | - | 1,689,979 | ||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling, general and administrative
|
27,527 | 1,015,249 | - | 1,042,776 | ||||||||||||
|
Income before other income / (expenses)
|
(27,527 | ) | 674,730 | - | 647,203 | |||||||||||
|
Depreciation and amortization
|
- | (33,372 | ) | (33,372 | ) | |||||||||||
|
Net income before income tax
|
(27,527 | ) | 641,358 | - | 613,831 | |||||||||||
|
Provision for income taxes
|
(825 | ) | (218,062 | ) | - | (218,887 | ) | |||||||||
|
Income (loss) from continuing operations
|
$ | (28,352 | ) | $ | 423,296 | $ | - | $ | 394,944 | |||||||
|
Net income (loss) per common share from continuing operations:
|
||||||||||||||||
|
Basic and diluted
|
(0.00 | ) | 4.27 | 0.03 | ||||||||||||
|
Diluted
|
$ | (0.00 | ) | $ | 4.27 | $ | 0.03 | |||||||||
|
Weight average common share outstanding:
|
||||||||||||||||
|
Basic and diluted
|
15,409,999 | 99,225 | (3,009,154 | ) | 12,500,070 | |||||||||||
|
See Notes to Unaudited Pro Forma Consolidated Financial Statements
|
||||||||||||||||
|
Pro Forma Adjustments
|
||||||||||||||||
|
The preceding unaudited condensed combined consolidated pro forma balance sheet has been prepared as if the Merger was completed on March 31, 2015; the preceding unaudited condensed combined consolidated pro forma statement of operations has been prepared as if the Merger was completed on April 1, 2015. The following is the pro forma adjustment:
|
||||||||||||||||
|
(a) Adjust the accounts of the companies to reflect the Merger resulting in Ameri & Partners, Inc. as the accounting acquirer. After the closing of the Merger and the Private Placement, the Company will have 12,500,070 shares of common stock outstanding.
|
||||||||||||||||
|
Income (loss) Per Share from Continuing Operations
|
||||||||||||||||
|
Pro forma basic and diluted shares outstanding include the weighted average number of common shares outstanding for Ameri & Partners, Inc. during the respective periods, in addition to the common stock issued as a result of the Merger assuming they had been issued at the beginning of the period. The common stock issued in connection with the Merger is assumed to be outstanding for the entire period presented.
|
||||||||||||||||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 6/1/15 | |||
| For Period End: | 5/26/15 | 4, 8-K | ||
| 4/1/15 | ||||
| 3/31/15 | 10-K, 10-Q | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/10/20 Enveric Biosciences, Inc. S-4/A 121:18M M2 Compliance LLC/FA 11/09/20 Enveric Biosciences, Inc. S-4/A 122:18M M2 Compliance LLC/FA 10/22/20 Enveric Biosciences, Inc. S-4/A 123:18M M2 Compliance LLC/FA 9/17/20 Enveric Biosciences, Inc. S-4/A 9/16/20 118:18M M2 Compliance LLC/FA 8/12/20 Enveric Biosciences, Inc. 10-K/A 12/31/19 82:6.1M M2 Compliance LLC/FA 8/12/20 Enveric Biosciences, Inc. S-4/A 113:17M M2 Compliance LLC/FA |